Use of clotting factor VII activity induced by therapy to treat serious bleeding

摘要

Severe bleeding caused by salpingo / fibrotic therapy, including intracranial hemorrhage, requires an effective dose of seven active (VIIa) coagulation factor or its functional derivative when treating patients with such bleeding.